Global Blood Therapeutics, Inc. Increase (Decrease) in Accounts Receivable
Global Blood Therapeutics, Inc. reported Increase (Decrease) in Accounts Receivable of $965.00 thousand for the 6-month period ending 2022-06-30, per its 10-Q filed 2022-08-08.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2022-08-08
- Global Blood Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2022-06-30 was $2.04M, a 59.11% increase year-over-year.
- Global Blood Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2022-03-31 was -$1.07M, a 239.87% decline year-over-year.
- Global Blood Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2021-12-31 was $4.91M, a 45.58% increase year-over-year.
- Global Blood Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2021-09-30 was $4.35M, a 162.21% increase year-over-year.
- Global Blood Therapeutics, Inc. increase (decrease) in accounts receivable for fiscal 2021 was $11.30M, a 23.97% decline from fiscal 2020.
- Global Blood Therapeutics, Inc. increase (decrease) in accounts receivable for fiscal 2020 was $14.86M, a 463.63% increase from fiscal 2019.
- Global Blood Therapeutics, Inc. increase (decrease) in accounts receivable for fiscal 2019 was $2.64M.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2022-06-30 | $2.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $965.00K 10-Q · filed 2022-08-08 | $5.87M derived: sum of 3 quarters · filed 2022-08-08 | $10.22M derived: sum of 4 quarters · filed 2022-08-08 |
| 2022-03-31 | -$1.07M 10-Q · filed 2022-05-04 | $3.84M derived: sum of 2 quarters · filed 2022-05-04 | $8.19M derived: sum of 3 quarters · filed 2022-05-04 | $9.46M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-12-31 | $4.91M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | $9.26M derived: sum of 2 quarters · filed 2022-02-23 | $10.54M derived: sum of 3 quarters · filed 2022-08-08 | $11.30M 10-K · filed 2022-02-23 |
| 2021-09-30 | $4.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $5.63M derived: sum of 2 quarters · filed 2022-08-08 | $6.39M 10-Q · filed 2021-11-04 | $9.76M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-06-30 | $1.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $2.04M 10-Q · filed 2022-08-08 | $5.41M derived: sum of 3 quarters · filed 2022-08-08 | $7.07M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $765.00K 10-Q · filed 2022-05-04 | $4.13M derived: sum of 2 quarters · filed 2022-05-04 | $5.79M derived: sum of 3 quarters · filed 2022-05-04 | $13.69M derived: sum of 4 quarters · filed 2022-05-04 |
| 2020-12-31 | $3.37M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | $5.03M derived: sum of 2 quarters · filed 2022-02-23 | $12.92M derived: sum of 3 quarters · filed 2022-02-23 | $14.86M 10-K · filed 2022-02-23 |
| 2020-09-30 | $1.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $9.55M derived: sum of 2 quarters · filed 2021-11-04 | $11.49M 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $7.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | $9.83M 10-Q · filed 2021-08-03 | ||
| 2020-03-31 | $1.94M 10-Q · filed 2021-05-05 | |||
| 2019-12-31 | $2.64M 10-K · filed 2022-02-23 |